Susquehanna International Group, LLP Nuvalent, Inc. Put Options Transaction History

Susquehanna International Group, LLP

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$67.44 - $112.17 $11.3 Million - $18.8 Million	167,900 Added 265.24%	231,200 $23.7 Million
Q2 2024 Aug 15, 2024	BUY	$62.76 - $81.61 $633,876 - $824,261	10,100 Added 18.98%	63,300 $4.8 Million
Q1 2024 May 07, 2024	BUY	$72.35 - $88.99 $1.39 Million - $1.71 Million	19,200 Added 56.47%	53,200 $3.99 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $661,752 - $1.25 Million	15,600 Added 84.78%	34,000 $2.5 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $719,808 - $917,240	18,400 New	18,400 $845,000

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.73B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.